• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胸腺神经内分泌肿瘤的治疗、预后标志物及生存情况:41例患者的单中心经验

Treatment, prognostic markers, and survival in thymic neuroendocrine tumors: A single center experience of 41 patients.

作者信息

Ma Kefeng, Liu Yi, Xue Zhiqiang, Chu Xiangyang

机构信息

Department of Thoracic Surgery, The Chinese People's Liberation Army General Hospital Department of Thoracic Surgery, Beijing Chao-Yang Hospital, Beijing, China.

出版信息

Medicine (Baltimore). 2017 Oct;96(43):e7842. doi: 10.1097/MD.0000000000007842.

DOI:10.1097/MD.0000000000007842
PMID:29068978
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5671811/
Abstract

Neuroendocrine tumors of the thymus (NETTs) are rare but aggressive, and lead to poor overall survival. This retrospective study was designed to analyze factors that correlate with the prognosis of patients with NETTs.From 1999 to 2015, 41 ongoing patients with NETTs were enrolled in this study. The clinical data and outcome were compiled. Overall survival (OS) rate was analyzed using the Kaplan-Meier method in univariate analysis and the Cox-model was used in multivariate analysis.Of the 41 NETTs patients analyzed (31 male and 10 female), 12 were typical carcinoma, 14 were atypical carcinoma, 14 were small-cell carcinoma and, 1 was large-cell carcinoma. The median follow-up time was 29 months (range, 9.0-69.0). In total, 25 patients died of cancer-related disease by the last follow-up. The 3- and 5-year survival rates for all patients were 42.7% and 23.4%, respectively. Among the prognostic factors analyzed by multivariate analysis, low tumor grade, complete resection, and a negative chromogranin A (CgA) expression were positively correlated with survival.The surgical treatment of NETTs, CgA negative, and low grade of NETTs were associated with a statistically significant better prognosis. However, large, multicenter studies are required to fully validate these prognostic factors.

摘要

胸腺神经内分泌肿瘤(NETTs)罕见但具有侵袭性,导致总体生存率较低。本回顾性研究旨在分析与NETTs患者预后相关的因素。1999年至2015年,41例NETTs患者纳入本研究。收集临床数据和结果。单因素分析采用Kaplan-Meier法分析总生存率(OS),多因素分析采用Cox模型。在分析的41例NETTs患者中(31例男性和10例女性),12例为典型癌,14例为非典型癌,14例为小细胞癌,1例为大细胞癌。中位随访时间为29个月(范围9.0 - 69.0)。截至最后一次随访,共有25例患者死于癌症相关疾病。所有患者的3年和5年生存率分别为42.7%和23.4%。多因素分析的预后因素中,低肿瘤分级、完整切除和嗜铬粒蛋白A(CgA)表达阴性与生存呈正相关。NETTs的手术治疗、CgA阴性和低分级NETTs与统计学上显著更好的预后相关。然而,需要大型多中心研究来充分验证这些预后因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdbb/5671811/1cb1dd314c2b/medi-96-e7842-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdbb/5671811/1cb1dd314c2b/medi-96-e7842-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cdbb/5671811/1cb1dd314c2b/medi-96-e7842-g006.jpg

相似文献

1
Treatment, prognostic markers, and survival in thymic neuroendocrine tumors: A single center experience of 41 patients.胸腺神经内分泌肿瘤的治疗、预后标志物及生存情况:41例患者的单中心经验
Medicine (Baltimore). 2017 Oct;96(43):e7842. doi: 10.1097/MD.0000000000007842.
2
Comparison of outcomes between neuroendocrine thymic tumours and other subtypes of thymic carcinomas: a joint analysis of the European Society of Thoracic Surgeons and the International Thymic Malignancy Interest Group.神经内分泌性胸腺肿瘤与其他胸腺癌亚型的预后比较:欧洲胸外科医师协会和国际胸腺恶性肿瘤兴趣小组的联合分析
Eur J Cardiothorac Surg. 2016 Oct;50(4):766-771. doi: 10.1093/ejcts/ezw107. Epub 2016 Mar 31.
3
Outcome of primary neuroendocrine tumors of the thymus: a joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases.胸腺原发性神经内分泌肿瘤的预后:国际胸腺恶性肿瘤兴趣小组和欧洲胸外科医师学会数据库的联合分析。
J Thorac Cardiovasc Surg. 2015 Jan;149(1):103-9.e2. doi: 10.1016/j.jtcvs.2014.08.061. Epub 2014 Sep 16.
4
Neuroendocrine tumors of the thymus: a clinicopathological and prognostic study.胸腺神经内分泌肿瘤:一项临床病理与预后研究
Ann Thorac Surg. 2001 Oct;72(4):1179-82. doi: 10.1016/s0003-4975(01)03032-6.
5
Neuroendocrine Tumors of the Thymus: Analysis of Factors Affecting Survival in 254 Patients.胸腺神经内分泌肿瘤:254例患者生存影响因素分析
Ann Thorac Surg. 2017 Mar;103(3):935-939. doi: 10.1016/j.athoracsur.2016.07.050. Epub 2016 Oct 6.
6
Development and validation of a nomogram prognostic model for patients with neuroendocrine tumors of the thymus.胸腺神经内分泌肿瘤患者列线图预后模型的建立和验证。
Thorac Cancer. 2020 Sep;11(9):2457-2464. doi: 10.1111/1759-7714.13556. Epub 2020 Jul 12.
7
Clinical evaluation of a new tumour-node-metastasis staging system for thymic malignancies proposed by the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee and the International Thymic Malignancy Interest Group.由国际肺癌研究协会分期与预后因素委员会和国际胸腺恶性肿瘤兴趣小组提出的胸腺恶性肿瘤新肿瘤-淋巴结-转移分期系统的临床评估。
Eur J Cardiothorac Surg. 2016 Feb;49(2):574-9. doi: 10.1093/ejcts/ezv389. Epub 2015 Nov 7.
8
Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.嗜铬粒蛋白A、分化程度及有丝分裂对直径≤2厘米的无功能胰腺神经内分泌肿瘤的影响
J Surg Res. 2017 May 1;211:206-214. doi: 10.1016/j.jss.2016.12.033. Epub 2016 Dec 29.
9
Surgical treatment and prognosis of thymic squamous cell carcinoma: a retrospective analysis of 105 cases.胸腺鳞状细胞癌的外科治疗和预后:105 例回顾性分析。
Ann Thorac Surg. 2013 Sep;96(3):1019-24. doi: 10.1016/j.athoracsur.2013.04.078. Epub 2013 Jul 16.
10
Prognostic impact of tumour size in completely resected thymic epithelial tumours.肿瘤大小对完全切除的胸腺上皮肿瘤的预后影响
Eur J Cardiothorac Surg. 2016 Dec;50(6):1068-1074. doi: 10.1093/ejcts/ezw178.

引用本文的文献

1
Treatment, Prognostic Markers, and Survival in Thymic Neuroendocrine Tumors, with Special Reference to Temozolomide-Based Chemotherapy.胸腺神经内分泌肿瘤的治疗、预后标志物及生存情况,特别提及基于替莫唑胺的化疗
Cancers (Basel). 2024 Jul 10;16(14):2502. doi: 10.3390/cancers16142502.
2
A Single Center Analysis of Thymic Neuroendocrine Tumors.胸腺神经内分泌肿瘤的单中心分析
Cancers (Basel). 2022 Oct 9;14(19):4944. doi: 10.3390/cancers14194944.
3
Multiple endocrine neoplasia 1: a broad overview.多发性内分泌腺瘤病1型:概述

本文引用的文献

1
Neuroendocrine Tumors of the Thymus: Analysis of Factors Affecting Survival in 254 Patients.胸腺神经内分泌肿瘤:254例患者生存影响因素分析
Ann Thorac Surg. 2017 Mar;103(3):935-939. doi: 10.1016/j.athoracsur.2016.07.050. Epub 2016 Oct 6.
2
The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes.《2015年世界卫生组织胸腺肿瘤分类:延续性与变化》
J Thorac Oncol. 2015 Oct;10(10):1383-95. doi: 10.1097/JTO.0000000000000654.
3
The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors.
Ther Adv Chronic Dis. 2021 Aug 12;12:20406223211035288. doi: 10.1177/20406223211035288. eCollection 2021.
4
Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid.卡培他滨和替莫唑胺治疗晚期胸腺非典型类癌的疗效观察。
Oncologist. 2019 Jun;24(6):798-802. doi: 10.1634/theoncologist.2018-0291. Epub 2018 Nov 9.
IASLC/ITMIG 胸腺上皮肿瘤分期项目:为即将发布的(第 8 版)TNM 恶性肿瘤分类制定基于循证医学的分期分类系统的建议。
J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S65-72. doi: 10.1097/JTO.0000000000000290.
4
Outcome of primary neuroendocrine tumors of the thymus: a joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases.胸腺原发性神经内分泌肿瘤的预后:国际胸腺恶性肿瘤兴趣小组和欧洲胸外科医师学会数据库的联合分析。
J Thorac Cardiovasc Surg. 2015 Jan;149(1):103-9.e2. doi: 10.1016/j.jtcvs.2014.08.061. Epub 2014 Sep 16.
5
Recurrence of thymic neuroendocrine carcinoma 24 years after total excision: A case report.胸腺神经内分泌癌全切术后24年复发:一例报告
Oncol Lett. 2013 Jul;6(1):147-149. doi: 10.3892/ol.2013.1327. Epub 2013 May 1.
6
Treatment, prognostic markers and survival in thymic neuroendocrine tumours. a study from a single tertiary referral centre.胸内神经内分泌肿瘤的治疗、预后标志物和生存。单中心三级转诊中心的研究。
Lung Cancer. 2013 Mar;79(3):289-93. doi: 10.1016/j.lungcan.2012.12.001. Epub 2013 Jan 1.
7
Primary neuroendocrine tumors of the thymus: a multicenter experience of 35 patients.胸腺原发性神经内分泌肿瘤:35 例多中心经验。
Ann Thorac Surg. 2012 Jul;94(1):241-5; discussion 245-6. doi: 10.1016/j.athoracsur.2012.03.062. Epub 2012 May 26.
8
NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus).NANETS 共识指南:胸部神经内分泌肿瘤(包括肺和胸腺)的诊断和管理:分化良好的神经内分泌肿瘤。
Pancreas. 2010 Aug;39(6):784-98. doi: 10.1097/MPA.0b013e3181ec1380.
9
Thymic neuroendocrine tumors: a SEER database analysis of 160 patients.胸腺神经内分泌肿瘤:SEER 数据库 160 例分析。
Ann Surg. 2010 Jun;251(6):1117-21. doi: 10.1097/SLA.0b013e3181dd4ec4.
10
Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up.神经内分泌支气管和胸腺肿瘤:ESMO关于诊断、治疗及随访的临床建议
Ann Oncol. 2009 May;20 Suppl 4:147-9. doi: 10.1093/annonc/mdp157.